GeneDx Holdings Corp. (WGS)

Market Cap	3.02B
Revenue (ttm)	362.32M
Net Income (ttm)	1.41M
Shares Out	28.73M
EPS (ttm)	0.05
PE Ratio	2,169.28
Forward PE	50.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	417,688
Open	107.47
Previous Close	105.95
Day's Range	102.97 - 108.41
52-Week Range	28.86 - 117.75
Beta	2.08
Analysts	Strong Buy
Price Target	99.29 (-5.56%)
Earnings Date	Jul 29, 2025

About WGS

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Employees: 1,000
• Stock Exchange: NASDAQ
• Ticker Symbol: WGS
• Website: https://www.genedx.com

Financial Performance

In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $99.29, which is a decrease of -5.56% from the latest price.

Price Target

$99.29

(-5.56% downside)

Analyst Consensus: Strong Buy